ArticleIndian journal of microbiology2025
Mucus-Penetrating PEGylated Nanoshuttle for Enhanced Drug Delivery and Healthcare Applications.
Article in Indian journal of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- mRNA-based therapeutics in lung Cancer: Mechanisms, applications, and translational challenges.Journal, genetic engineering & biotechnology · 2026Review
- Emerging Technologies for Oral Peptide Delivery: From Bioinspired Systems to Smart Device-Assisted Drug Delivery.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Nanotechnology-Enabled Strategies to Overcome Antibiotic Resistance in Respiratory Infections: Mechanisms, Platforms, and Translational Challenges.Biomedicines · 2026Review
- Recent Advances in Extended Ocular Drug Delivery for the Ocular Surface.Molecules (Basel, Switzerland) · 2026Review
- Targeted inhibition of ATP synthase subunit c by pp10-loaded inhalable albumin nanoparticles ameliorates airway inflammation in asthma.Journal of nanobiotechnology · 2026Article
- Chitosan Nanoparticles for Natural Antioxidant Delivery in Metabolic Dysfunction-Associated Steatohepatitis Liver Disease (MASLD).International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The delivery of therapeutic agents across mucosal barriers represents a significant challenge in drug delivery due to the protective nature of mucus layers that line various human body cavities. These barriers are challenging in treating ailments where targeted delivery could substantially improve therapeutic outcomes. Conventional drug delivery systems often face limitations in penetrating the mucus layer, leading to reduced efficacy, lower bioavailability, and increased need for higher dosages, which can cause adverse side effects. This manuscript introduces Mucus-penetrating PEGylated Nanoshuttles (MPNS) as a pioneering strategy designed to overcome these challenges. MPPNSs are engineered with specific surface properties and sizes that allow them to traverse the mucus barrier efficiently without becoming trapped, providing a promising solution for enhanced drug delivery to mucosal tissue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.